{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T01:39:55Z","timestamp":1711071595814},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1697","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA is requiring a boxed warning in the label of denosumab (Prolia \u2013 Amgen), a monoclonal antibody that inhibits osteoclasts, about an increased risk of severe hypocalcemia in patients with advanced chronic kidney disease (CKD; eGFR &lt;30 mL\/min\/1.73 m2), particularly those on dialysis. FDA-approved indications for Prolia are listed in Table 1.<\/jats:p>","DOI":"10.58347\/tml.2024.1697c","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T18:49:11Z","timestamp":1711046951000},"page":"40-40","source":"Crossref","is-referenced-by-count":0,"title":["In Brief: Severe Hypocalcemia with Denosumab (Prolia) in Chronic Kidney Disease"],"prefix":"10.58347","volume":"66","member":"37151","published-online":{"date-parts":[[2024,3,4]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T18:49:20Z","timestamp":1711046960000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1697c"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":0,"journal-issue":{"issue":"1697","published-online":{"date-parts":[[2024,3,4]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1697c","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]}}}